Oxford Nanopore Tech shares tank on margin warning
(Sharecast News) - Shares in Oxford Nanopore Technologies plunged on Tuesday after the DNA/RNA sequencing tech firm warned of lower full-year margins due to a change in a purchase agreement to do with the Emirati Genome Program.
The EGP contract, which was originally signed in November 2021 over a three-year period, has been extended to the end of 2026. However, the outstanding purchase commitment under the original agreement has now been removed.
ONT has now signed an agreement to replace and supersede the existing purchase agreement it has with G42 Laboratories in support of the EGP.
Excluding EGP, group gross margins are expected to have been 57% for the 2023 full year, in line with prior guidance. However, as a result of the G42 agreement, they are tipped to fall to between 53% and 55%.
Ahead of its annual results in March, the company said it expects to report Life Science Research Tools revenue of £169m, up 15% on 2022.
Excluding revenues from the EGP and Covid-19 sequencing, which heavily affected 2022 results, revenue growth would have been 39% on a constant currency basis, though underlying growth was held back by a slower-than-expected ramp-up of certain customers in the S3 customer group, it said.
"In addition, there was some slow-down in growth in China and in the Middle East following issuance of the recent US semiconductor trade rule further regulating sales of advanced AI semiconductors. Product development plans within 2024 include updates that are expected to mitigate this headwind," the company explained.
The stock was down 14% at 173p by 1116 GMT.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.